4. Agreement of the minutes and review of actions from BPC Housekeeping issues For information

Transcription

1 23 February 2018 BPC-A _rev2 Draft agenda 24 th meeting of the Biocidal Products Committee (BPC) 6 7 March 2018 ECHA Conference Centre, Annankatu 18, Helsinki Starts on 6 March at 09:30, ends on 7 March at 13:00 1. Welcome and apologies 2. Agreement of the agenda BPC-A Declarations of potential conflicts of interest to agenda items 4. Agreement of the minutes and review of actions from BPC-23 BPC-M Administrative issues 5.1. Housekeeping issues 5.2. Other administrative issues and report from other Committees BPC Mandate of the Ad-hoc Working Group Environmental Exposure BPC

2 6. Work programme for BPC 6.1. Revised BPC Work Programme BPC Outlook for BPC BPC New requests from the Commission related to Article 38 and Article 75(1)(g) BPC BPC and agreement 7. Applications for approval of active substances * 7.1. Working procedure for active substance approval BPC Draft BPC opinion on salicylic acid for PT 2, 3, 4 Previous discussion(s): WG-V-2017 PT2: BPC A, B, C PT3: BPC A, B, C PT4: BPC A, B, C 7.3. Draft BPC opinion on 2-Phenoxyethanol for PT 1, 2, 4 Previous discussion(s): WG-IV-2017 PT1: BPC A, B, C PT2: BPC A, B, C PT4: BPC A, B, C * For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft assessment report (AR) which may cover more than one PT (denoted by B) and a document containing open issues covering all the PTs to be discussed for that substance (denoted by C). 2

3 7.4. Revised Assessment Report following the submission of data after active substance approval: Transflutrhin for PT 18 BPC A, B Bacillus thuringiensis subsp. Kurstaki for PT 18 and for copper thiocyanate, dicopper oxide and copper flakes (coated with aliphatic acid) for PT Assessment of endocrine disrupting properties in active substance approval BPC For discussion and agreement Item 8 Union authorisation 8.1 Update on Union authorisation 8.2 Draft BPC opinion on Union authorisation application for product families containing iodine / PVP-iodine BPC A, B, C and D 8.3 Iodate in biocidal products containing iodine / PVP-iodine as active substance: TAB entry BPC Item 9 Dermal absorption 9.1 Guidance document on dermal absorption BPC For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft Summary of Product Characteristics (SPC) (denoted by B), a draft product assessment report (PAR) (denoted by C) and a document containing open issues to be discussed for the biocidal product or biocidal product familiy (denoted by D). 3

4 Item 10 Assessment of relevant impurities 10.1 ECHA proposal for timelines on preparing guidance on the assessment of relevant impurities BPC For discussion and agreement Item 11 Treated articles 11.1 Risk assessment for treated articles / materials at active substance approval stage and the consequences for risk mitigation BPC For discussion Item 12 Any other business 12.1 Harmonised List of Endpoints for pyrethroid metabolites BPC Item 13 Action points and conclusions 4

5 Provisional time schedule for the 24 th meeting of the Biocidal Products Committee (BPC) ECHA Conference Centre, Annankatu 18, Helsinki 6 March 2018: starts at 09:30; 7 March ends at 13:00 Please note that the time schedule indicated below are provisional and subject to possible change. The schedule is distributed to participants on a preliminary basis. If needed, followup discussions may take place on the following day for BPC opinions. Tueday 6 March: morning session Items 1-5 Opening items and administrative issues Item 6 Work programme of the BPC Item 7.2 Draft BPC opinion on salicylic acid for PT 2, 3, 4 Tuesday 6 March: afternoon session Item 7.3 Draft BPC opinion on 2-Phenoxyethanol for PT 1, 2, 4 Item 7.4 Revised Assessment Report following the submission of data after active substance approval: Item 7.1 Item 7.5 Item 9.1 Item Transflutrhin for PT Bacillus thuringiensis subsp. Kurstaki for PT 18 and for copper thiocyanate, dicopper oxide and copper flakes (coated with aliphatic acid) for PT 21 Working procedure for active substance approval Assessment of endocrine disrupting properties in active substance approval Guidance document on dermal absorption ECHA proposal for timelines on preparing guidance on the assessment of relevant impurities Wednesday 7 March: morning session Item 8.1 Item 8.2 Item 8.3 Item 11.1 Item 12 Item 13 Update on Union authorisation Draft BPC opinion on Union authorisation application for product families containing iodine / PVP-iodine Iodate in biocidal products containing iodine / PVP-iodine as active substance: TAB entry Risk assessment for treated articles / materials at active substance approval stage and the consequences for risk mitigation AOB: 12.1: Harmonised List of Endpoints for pyrethroid metabolites Action points and conclusions End of meeting o0o 5